Pfizer’s Ibrance fails to meet primary endpoint in early breast cancer trial

This article was originally published here

The phase 3 PENELOPE-B trial has failed to achieve the primary endpoint of improved invasive disease-free survival (iDFS) in women with hormone receptor-positive (HR+), human epidermal growth factor-negative

The post Pfizer’s Ibrance fails to meet primary endpoint in early breast cancer trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply